Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions

“…The U.S. map in Figure 1 shows the locations of MSAs in which pneumococcal vaccination coverage rate among the study population was higher or lower than the national average (a different version of this figure was previously published). 13 As shown in the map, a majority of the MSAs located in the U.S. Department of Health and Human Services (HHS) region of Seattle (15 out of 25) had vaccination coverage rates higher than the national average. In contrast, a majority of the MSAs in the San Francisco (24/34) and Atlanta (56/92) regions had lower pneumococcal vaccination coverage than the national average.…”

“…A total of 255,330 adults met all inclusion criteria and were included in the analysis (Attrition of study adults was described in a previous study). 13 Table 1 summarizes the mean (SD) characteristics of the MSAs represented in the dataset. The proportion of newly diagnosed adults receiving a pneumococcal vaccination during the follow-up period was 13.4% across MSAs.…”

“…Previous studies have found substantial inter-state and inter-region variations in vaccination coverage for pneumococcal and other adult vaccines, after accounting for patient-level characteristics. 13 , 31 The current study went one step further to examine regional factors associated with vaccination. To our knowledge, this study has been the first to examine regional factors associated with pneumococcal vaccination coverage at the MSA level among adults with underlying conditions.…”

“… 12–16 There are also regional variations in pneumococcal vaccination coverage even after accounting for individual-level factors; however, there are limited published data on factors associated with this variation. 13 The objective of this study was to examine regional variation in pneumococcal vaccination coverage among adults with underlying conditions, and to identify regional factors associated with pneumococcal vaccination.…”

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

“…They reported that, despite a high risk of invasive pneumococcal disease, the adults with cancer were less likely to be vaccinated than adults with diabetes mellitus or HIV. The authors proposed as a possible explanation of these results the multidisciplinary approach adopted in care for HIV/AIDS or diabetes mellitus and suggested that a comprehensive and multidisciplinary care model might improve the pneumococcal vaccination coverage in vulnerable subjects [ 80 ]. Mohr and colleagues analyzed the vaccination status of lung cancer patients treated at the University Hospital Regensburg, Germany in a prospective, single-center study with the evidence of a very low rate (9.4%) of the vaccinated patients [ 81 ].…”